Synthonix has focused on inspiring medicinal chemists to push the boundaries of drug discovery.

Since 2003 we have designed our products to be biologically relevant based on factors such as rotatable bonds, unusual bond angles, multiple functionalities, metabolic stability, molecular weight, water solubility, sp3 hybridization, and three dimensional structure, making them more amenable to protein interaction.

The result is more effective tools for drug discovery and faster lead identification, with medicinal chemists able to access more biologically active chemical space.



As our bond to our customers, we promise to be:


We work closely with the chemistry community to identify the most impactful molecules and make them commercially available, allowing you to make the best targets for your projects.


We have an inventory level of > 95%, tracked deliveries with global couriers, and rigorous analytical procedures to help you plan and organize your research with confidence and trust.


We aim to make our systems simple, our interfaces intuitive, and our interactions informative so that working with us make it easier to do your job.


We use recycled and recyclable packaging wherever possible in order to reduce not only environmental impact, but yours too.


Executive Staff

Dr. Gary Allred

Co founder, President & CEO

In addition to his extensive chemical and pharmaceutical expertise, Dr. Allred has over 20 years experience in business development and management, intellectual property development, patent filing and prosecution, strategic and portfolio planning, contract negotiation, technology assessment, and competitive intelligence.

Before co-founding Synthonix Corporation in 2003, Dr. Allred founded a successful start-up in 1997 where he served as President and CEO. Prior to this he received his Ph.D. in organic chemistry from Emory University under Dr. Lanny Liebeskind.

Dr. Allred performed research in copper-mediated and palladium-catalyzed coupling reactions, boron chemistry, battery technology, and silane chemistry. He authored several papers in peer-reviewed journals and is an inventor of seven patents.

Jonathan Scoggins

Co-founder, Vice-President

Jonathan Scoggins is the co-founder of Synthonix Inc. He currently serves as Vice President of Synthonix. Jonathan has over 12 years of experience in the custom chemical business. Jonathan’s main focus with Synthonix is business management and business development.

Before co-founding Synthonix Inc. Jonathan founded Ryscor Science Inc in 1998 where he served as President and CEO until starting Synthonix in 2003. Ryscor Science was a specialty chemical company that specialized in boronic acids as well as other boron containing compounds used in various areas of medicinal research and development.

When Ryscor Science was formed the core focus was supplying boron-10 labeled amino acids for use in BNCT (boron neutron capture therapy) which was and still is a promising therapy for use on various types of malignant brain tumors. Jonathan received his undergraduate degree from North Carolina State University in 1996.







US Site


Our products are manufactured in our 10,000 sq. ft. facility located in Wake Forest, NC. We are located only minutes away from the famous Research Triangle Park and from RDU International airport.




World Preclinical Congress 2017

06/12/2017 - 06/16/2017

Boston, MA

World Preclinical Congress 2017

The Westin Copley Place